Research programme: antibacterials - Durata
Alternative Names: 7-Methyl lincosamides - Durata; Lincosamides - Durata; Peptide deformylase inhibitors - Durata; PF-03438011; PF-03438012; VIC 105403; VIC 105404; VIC 105555; VIC 200603; VIC 5555; VIC 603; VRC-3950Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator Vicuron Pharmaceuticals
- Class Azetidines; Ketolides; Macrocyclic compounds; Sulfonamides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bacterial infections
- Discontinued Mycoses
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections in USA
- 06 Oct 2014 Durata Therapeutics enters into a definitive merger agreement with Actavis
- 27 Jan 2006 Data presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2005) have been added to the pharmacokinetics and Bacterial infections antimicrobial activity ,,," />) and pharmacodynamics sections